Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 3/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8797662 | 0.95 | LPAR1 (0.46) | LPAR1TBXA2RTP53KMT2ALMNA | |
| SCHEMBL8797449 | 0.93 | LPAR1 (0.44) | LPAR1TBXA2RTP53KMT2ALMNA | |
| SCHEMBL8797883 | 0.93 | LPAR1 (0.46) | LPAR1TBXA2RTP53KMT2ALMNA | |
| SCHEMBL8797028 | 0.91 | TBXA2R (0.38) | LPAR1TBXA2RTP53KMT2ALMNA | |
| SCHEMBL8797886 | 0.90 | LPAR1 (0.42) | LPAR1TBXA2RTP53KMT2ALMNA | |
| SCHEMBL8797336 | 0.90 | LPAR1 (0.39) | LPAR1TBXA2RKMT2ALMNASMN1; SMN2 | |
| SCHEMBL8797272 | 0.88 | TP53 (0.45) | LPAR1TBXA2RTP53KMT2ALMNA | |
| SCHEMBL8798173 | 0.88 | TP53 (0.47) | TP53KMT2ALMNAHDAC4HDAC7 | |
| SCHEMBL8797541 | 0.87 | LPAR1 (0.45) | LPAR1TP53KMT2ALMNASMN1; SMN2 | |
| SCHEMBL8797451 | 0.87 | TP53 (0.39) | LPAR1TP53KMT2ALMNAHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0497201-B1 | Tricyclic compounds and intermediates thereof | KYOWA HAKKO KOGYO KK (JP) | 1997-01-15 | — | — | EP | claimed |
| US-5340807-A | Tricyclic compounds and intermediates thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-08-23 | — | — | US | claimed |
| EP-0497201-A1 | Tricyclic compounds and intermediates thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1992-08-05 | — | — | EP | claimed |
| US-7799860-B2 | Composition improved in the solubility or oral absorbability | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-7799860-B2 | Composition improved in the solubility or oral absorbability | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| WO-2008058383-A1 | ACAT INHIBITORS AND THEIR USE IN THE PREVENTION OR TREATMENT OF FIBROSIS | CHRONOGEN INC. (CA) | 2008-05-22 | — | — | WO | disclosed |
| US-20070065516-A1 | Composition improved in the solubility or oral absorbability | KYOWA HAKKO KOGYO CO., LTD. | 2007-03-22 | — | — | US | disclosed |
| US-20070065516-A1 | Composition improved in the solubility or oral absorbability | KYOWA HAKKO KOGYO CO., LTD. | 2007-03-22 | — | — | US | disclosed |
| EP-0497201-B1 | Tricyclic compounds and intermediates thereof | KYOWA HAKKO KOGYO KK (JP) | 1997-01-15 | — | — | EP | disclosed |
| US-5478835-A | Acyl coenzyme A: acyltransferase inhibitors; treatment of hyperlipemia and arteriosclerosis | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-12-26 | — | — | US | disclosed |
| US-5340807-A | Tricyclic compounds and intermediates thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-08-23 | — | — | US | disclosed |
| EP-0497201-A1 | Tricyclic compounds and intermediates thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1992-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070065516-A1 | Composition improved in the solubility or oral absorbability | SI, SLC10A2, FABP2 | LPAR1 3981/4885TBXA2R 2754/4885TP53 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.